Table 2 Clinical characteristics and outcomes of NeurocovBR patients
From: Neurological syndromes associated with COVID-19: a multicenter study in Brazil
| Â | All patients | Vascular | Encephalopathy | Encephalitis | GBS | Neuropathies | Myelitis | ||
|---|---|---|---|---|---|---|---|---|---|
n, (%) | 197 (100) | 81 (41.1) | 68 (34.5) | 19 (9.6) | 13 (6.6) | 12 (6.1) | 4 (2.1) | ||
mRS at admission, n, (%) | |||||||||
 < 3 | 63 (32) | 11 (13.6) | 39 (57.4) | 5 (26.3) | 1 (7.7) | 6 (50) | 1 (25) | ||
 ≥ 3 | 132 (67) | 69 (85.2) | 28 (41.1) | 14 (73.7) | 12 (92.3) | 6 (50) | 3 (75) | ||
 unknown | 2 (1) | 1 (1.2) | 1 (1.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
Specific scales at admission, n, (%) | |||||||||
 GCS 9—12 | _ | 24 (29.6) | 4 (6.5) | 3(15.8) | _ | _ | _ | ||
 GCS < 9 | _ | 30 (37) | 5 (7.4) | 3(15.8) | _ | _ | _ | ||
 LOS 3 | _ | _ | 17 (25) | 7 (36.8) | _ | _ | _ | ||
 LOS < 3 | _ | _ | 32 (47) | 2 (10.5) | _ | _ | _ | ||
 NIHSS 6—15 | _ | 21 (26) | _ | _ | _ | _ | _ | ||
 NIHSS > 15 | _ | 42 (51.9) | _ | _ | _ | _ | _ | ||
 ONLS 5—9 | _ | _ | _ | _ | 5 (38.5) | 1 (8.3) | _ | ||
 ONLS > 9 | _ | _ | _ | _ | 4 (30.8) | 3 (25) | _ | ||
Hospitalization, n, (%) | |||||||||
 Yes | 156 (79.2) | 72 (88.9) | 46 (67.6) | 14 (73.7) | 12 (92.3) | 10 (83.3) | 2 (50) | ||
 Needed ICU | 137 (60.5) | 65 (80.2) | 45 (66.2) | 11 (57.9) | 6 (46.2) | 9 (75) | 1 (25) | ||
 Needed MV | 103 (52.3) | 55 (67.9) | 28 (41.2) | 8 (42.1) | 4 (30.8) | 8 (66.7) | 0 (0) | ||
 Neurocovid identified during hospitalization | 82 (41.6) | 42 (51.9) | 27 (39.7) | 5 (26.3) | 1 (7.7) | 7 (58.3) | 0 (0) | ||
 Neurocovid identified after extubating | 37 (18.8) | 6 (7.4) | 20 (29.4) | 2 (10.5) | 1 (7.7) | 8 (66.7) | 0 (0) | ||
 Δt hospitalization, d, median, (IQR) | 22 (11–44) | 13 (6.5–22) | 24 (11–42) | 17.5 (9.25–51) | 15 (13–21) | 36 (17–48) | 11 (10–17) | ||
In-hospital complications, n, (%) | |||||||||
 Co-infections | 104 (52.8) | 55 (67.9) | 26 (38.2) | 10 (52.6) | 4 (30.8) | 8 (66.7) | 1 (25) | ||
 AKI with dialysis | 41 (20.8) | 26 (32.1) | 12 (17.6) | 1 (5.3) | 0 (0) | 2 (16.7) | 0 (0) | ||
 AKI without | 39 (19.8) | 22 (27.2) | 10 (14.7) | 5 (26.3) | 0 (0) | 2 (16.7) | 0 (0) | ||
Specialist decision treatments, n, (%) | |||||||||
 HCQ | 9 (4.6) | 2 (2.5) | 5 (7.4) | 1 (5.3) | 0 (0) | 1 (8.3) | 0 (0) | ||
 Anticoagulants | 131 (66.5) | 62 (81.5) | 34 (50) | 12 (63.2) | 8 (61.5) | 7 (58.3) | 0 (0) | ||
 Corticosteroid therapy | 125 (63.5) | 53 (65.4) | 42 (61.8) | 16 (84.2) | 3 (23.1) | 8 (66.7) | 3 (75) | ||
 Tocilizumab | 2 (1) | 0 (0) | 1 (1.5) | 0 (0) | 1 (7.7) | 0 (0) | 0 (0) | ||
Outcomes | |||||||||
 Death, n, (%) | 57 (28.9) | 45 (55.6) | 8 (11.8) | 3 (15.8) | 0 (0) | 1 (8.3) | 0 (0) | ||
 Δt COVID-death, d, median (IQR) | 24 (17–34) | 22 (16.5–29.5) | 30 (24.5–64) | 92 (72.2–106) | - | 43 | -_ | ||
 Δt Neurocovid-death, d, median, (IQR) | 15 (7–24) | 11.5 (6–21.5) | 18.5 (15–40.8) | 72.5 (62.8–85.8) | - | 18 | - | ||